Journal article
Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors
Abstract
BACKGROUND: Monitoring anticoagulation with activated clotting time (ACT) has been proposed to reduce ischemic or bleeding events. However, the value of using ACT to improve outcomes is uncertain. This study sought to determine the relationship between ACT and outcomes during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) treated by unfractionated heparin with GPIs (glycoprotein …
Authors
Dillinger J-G; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD
Journal
Circulation Cardiovascular Interventions, Vol. 11, No. 6,
Publisher
Wolters Kluwer
Publication Date
June 2018
DOI
10.1161/circinterventions.118.006084
ISSN
1941-7640
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Acute Coronary SyndromeAgedAnticoagulantsBlood CoagulationCyclic N-OxidesDrug Dosage CalculationsDrug MonitoringEptifibatideFactor Xa InhibitorsFemaleHemorrhageHeparinHumansMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsPyridinesRisk FactorsTime FactorsTreatment OutcomeWhole Blood Coagulation Time